Is Gilead (GILD) One of the Most Undervalued NASDAQ Stocks to Buy Right Now?

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 25, Gilead Sciences announced FDA approval for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). It is now approved as a single agent or in combination with Keytruda, becoming the first antibody-drug conjugate authorized for this setting regardless of PD-L1 status.

The approval follows successful Phase 3 trials showing significantly improved progression-free survival and more durable responses compared to standard chemotherapy. Based on these results, the National Comprehensive Cancer Network now lists Trodelvy as a category 1 preferred first-line treatment.

Is Gilead (GILD) One of the Most Undervalued NASDAQ Stocks to Buy Right Now?

This milestone expands Trodelvy’s clinical utility, building on its existing use in later-stage breast cancer treatments. With over 75,000 patients treated globally, this new indication provides a vital standard-of-care option for a disease that has historically lacked diverse first-line therapies.

Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.

While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1